Bamethan

In the field of cardiovascular diseases, vasodilator drugs are one of the core drug categories for improving peripheral circulation disorders and relieving related ischemic symptoms. As a representative papaverine-class peripheral vasodilator, bamethan exerts a vasodilatory effect by directly acting on vascular smooth muscle and blocking calcium ion influx, which can reduce peripheral vascular resistance and increase limb blood flow. Clinically, it is mainly used to treat diseases caused by vasospasm or stenosis such as acroarteriospasm, obliterative angiitis, chilblain, and migraine, and can also assist in improving the symptoms of poor peripheral circulation caused by hypertension. The applicable population covers adult patients with chronic peripheral circulation disorders.

At present, the global market size of bamethan is small, mainly concentrated in regions where it was launched earlier such as Europe and Japan. The market growth rate has remained at around 3% in the past five years, and the overall market pattern is dominated by generic preparation enterprises. There is no publicly verifiable national market size and growth rate data of bamethan in China, and its domestic clinical application is still in the stage of a niche category, which has not been included in the scope of national centralized volume-based procurement.

The original research enterprise of bamethan is Japan Organo Pharmaceutical Co., Ltd., and the original research trade name is "パパベリン塩酸塩" (a related dosage form previously used for papaverine hydrochloride, and the original research preparation related to bamethan has not been approved for marketing in China). There is no publicly verifiable expiration time of core patents, and the main dosage form of the original research is tablet. No relevant information that this variety is included in the Chinese *Catalogue of Chemical Drugs* or the FDA Reference Preparation Catalogue has been found. There is no registered DMF filing number of bamethan API in China, nor is there any bamethan preparation variety approved for marketing in China. (Data as of October 2025, please refer to the official website of CDE for the latest information)

CATO can provide a full set of impurity reference standards for bamethan API. Most of the products are in stock, and orders for in-stock products placed before 16:00 will be shipped on the same day. All reference standards comply with the compliance requirements of multiple regulations such as the Chinese Pharmacopoeia and FDA, and can fully meet the demand for impurity reference standards in the links of API R&D, quality research and registration declaration.